meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced mGC or mGEJC
mGC or mGEJC - 1st line (L1)
mGC or mGEJC - L1 - all population
mGC or mGEJC - L1 - HER2 neg/PDL1 positive
2
mGC or mGEJC - L1 - HER2 negative
1
mGC or mGEJC - L1 - HER2 positive
mGC or mGEJC - L1 - PDL1 positive
4
mGC or mGEJC - 2nd Line (L2)
mGC or mGEJC - L2 - all population
4
mGC or mGEJC - L2 - PDL1 positive
1
mGC or mGEJC - maintenance (M)
mGC or mGEJC - M - HER2 negative
1
mGC or mGEJC - M - HER2 neg/PDL1 positive
1
gene alteration defined cancer
<span style="margin-left: 0em;">chemotherapy</span>
<span style="margin-left: 1em;">Standard of Care (SoC) <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 0em;">immune chekpoint inhibitors</span>
<span style="margin-left: 1em;">anti-PD-(L)1</span>
<span style="margin-left: 2em;">avelumab based treatment</span>
<span style="margin-left: 3em;">avelumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (2)
progression or deaths (PFS) (2)
objective responses (ORR) (1)
DCR (1)
DOR (1)
AE (any grade) (1)
TRAE (any grade) (1)
SAE (any grade) (1)
AE leading to treatment discontinuation (any grade) (1)
TRAE (grade 3-4) (1)
AE (grade 3-4) (1)
TRAE leading to death (grade 5) (1)
TRAE leading to discontinuation (any grade) (1)
AE leading to death (grade 5) (1)
STRAE (any grade) (1)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
Evidence network for deaths_(OS)
2
JAVELIN Gastric 100, 2020 JAVELIN Gastric 100 (PDL1>1%), 2020
Standard of Care (SoC)
avelumab alone
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
Standard of Care (SoC)
avelumab alone
Standard of Care (SoC)
---
NA
avelumab alone
NA
---
pathologies: 185,186,304 - treatments: 417
result logic
×
Study list
